SuperworthBenitec Biopharma BNTC
- Market cap
- $301.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Benitec Biopharma's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | n/a | $0 | $0 | $0 | n/a | |
| R&D | $4.4M+67% | $5.1M+36% | $2.6M−19% | $3.5M+10% | $3.6M−19% | $5.4M+6% | $6.5M+153% | $2.9M−18% | $3.4M−6% | $5.8M+8% | $6.3M−3% | $7.9M+175% |
| SG&A | $1.6M−19% | $1.8M−2% | $1.6M+29% | $2M+49% | $2.2M+42% | $5.4M+197% | $8.8M+460% | $7M+242% | $6.4M+192% | $7.5M+39% | $7.3M−18% | $6.5M−6% |
| −$5.9M+28% | −$6.9M+24% | −$4.1M−5% | −$5.5M+22% | −$5.8M−1% | −$10.8M+56% | −$15.3M+270% | −$9.8M+77% | −$9.8M+69% | −$13.4M+24% | −$13.6M−11% | −$14.4M+47% | |
| Interest expense | $6K−33% | $6K−33% | $4K−43% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$6M+17% | −$6.8M+26% | −$4.3M−3% | −$4.7M+1% | −$5.1M−15% | −$9.6M+41% | −$14.5M+239% | −$8.8M+87% | −$9M+77% | −$11.8M+24% | −$11.9M−18% | −$12.8M+46% |
| −$3.05−62% | −$2.64−21% | −$0.23−91% | −$0.60−79% | −$0.18−94% | −$0.26−90% | −$0.38+65% | −$0.21−65% | −$0.22+22% | −$0.26+0% | −$0.24−37% | −$0.26+24% | |
| 2.2M+238% | 2.6M+59% | 18.3M+1011% | 8.9M+442% | 27.9M+1193% | 37.3M+1346% | 38.6M+111% | 41.2M+361% | 41.5M+49% | 46M+23% | 49.4M+28% | 49.4M+20% |
EPS, diluted: 7 periods, Q4 FY20 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY20 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Benitec Biopharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BNTCBenitec Biopharma | $301.7M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Benitec Biopharma
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .